A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets.
about
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationA therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationComparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationProphylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantationProphylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantationLeucoreduction of blood components: an effective way to increase blood safety?Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusionPlatelet Vascular Endothelial Growth Factor is a Potential Mediator of Transfusion-Related Acute Lung Injury.Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial.Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses.The practice of platelet transfusion in the intensive care unit.A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation.A randomized noninferiority crossover trial of corrected count increments and bleeding in thrombocytopenic hematology patients receiving 2- to 5- versus 6- or 7-day-stored platelets.Preoperative platelet transfusions and perioperative red blood cell requirements in patients with thrombocytopenia undergoing noncardiac surgery.I am the 9%: Making the case for whole-blood platelets.Cost-effectiveness of leucoreduction for prevention of febrile non-haemolytic transfusion reactionsDefining risk factors and presentations of allergic reactions to platelet transfusionLeukoreduced blood components: Advantages and strategies for its implementation in developing countries.Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation.The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC.Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products.Pulmonary transfusion reactions.Efficacy and Adverse Events of Platelet Transfusion Product-Specific Differences.Transfusion and component characteristics are not associated with allergic transfusion reactions to apheresis platelets.Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies.Transfusion-related adverse events at the tertiary care center in North India: An institutional hemovigilance effort.Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice?The top ten list of randomized controlled trials in transfusion medicine.A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia.Evidence-based decision making in transfusion medicine.Safety of platelet transfusion: past, present and future.A comparison of adverse reaction rates for PAS C versus plasma platelet units.Transfusion premedication practices among pediatric health care practitioners in Canada: results of a national survey.Development of a novel multiplexed assay for quantification of transforming growth factor-β (TGF-β).Current status of additive solutions for platelets.Feeling the burn: the significant burden of febrile nonhemolytic transfusion reactions.Effects of prestorage vs poststorage leukoreduction on the rate of febrile nonhemolytic transfusion reactions to platelets.A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment.An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment.Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction.
P2860
Q24186359-8781CF15-A8FF-44D9-8208-73EA1CB3B856Q24186913-62A2A7C8-FACB-4063-A409-CAF657AB460DQ24187751-5F8ACA99-D60D-4BBB-9B85-73D0C6C749FFQ24197779-0A57AA27-DFB3-436D-B5BD-FB073B833F6BQ24245960-15BF2B4F-4B39-4AB7-96DD-9D05E7DDFB12Q26771857-2AC25ACC-676A-49AD-BFE7-32254B7EC041Q28221912-0EF28278-9640-4443-A3E6-54EC248E6AF0Q30300632-85F2697E-EA5A-4152-B45C-5537FB085699Q33366635-76DAA9FC-4101-49A6-811D-88E748B0EE8FQ33372452-BF06A6CF-A18D-4E2E-8EC0-064D65082FF9Q33375078-BAD8375D-1532-49E0-BD13-60FDA3136D63Q33376798-2E4F362D-0CAB-4255-8805-222116819D2AQ33420765-8C4C1F5D-E225-4DC3-8352-FDD646AEEAEAQ33427502-B62FB4D7-5E78-4DDC-A1E7-F30FDDDF4FE6Q33432190-1DE3265D-8CB9-4539-85F2-3A24BBFE7223Q33690883-EC905387-419F-42FC-A93A-7684B1C7A177Q33693209-67E84B85-C939-4BC5-A922-C66F21F8067BQ33760699-6B7CFF4D-71EE-4921-A98A-A999362F6B88Q34154813-0AC1D8C8-14FF-42D3-B761-F16724A99908Q34285935-40C82B6F-7D00-40AF-AA3B-115298A8E867Q34777779-2E878556-F2D3-49AD-9A33-CE39320D770DQ34790939-DA25A69C-4F42-4A23-90B4-C1EBC8C0B2C2Q34791060-93382A3F-DB65-4C11-953F-09C3486BB7C4Q35091355-3667B8F8-A01F-4822-A971-9264019FDF3DQ35131637-91147050-BF58-465C-B877-9EC6262460A7Q35174050-D3F715B7-1318-4437-B702-ECBCF21E7442Q35792449-CB198127-C1CB-4B35-ABFF-5EF89E78ED7FQ35813075-8E9377F3-C219-4C45-A130-A798623756F5Q36492560-07068068-81FA-420A-A52E-38011DCE5262Q36588343-148819A0-8662-42C1-BFD0-E7097FC7C99DQ38197714-7CD53241-54A4-4A00-93FD-5D76E84326D2Q38204784-5A1C8937-B22C-4E56-969E-44FA7DBB4117Q38852062-C9E95838-A2BC-41AB-B21D-3C3D74A2EEB8Q38920213-B4A9FA8E-B387-4D33-95DF-649BE674F973Q39657480-02DB3AA6-2356-45B3-83B1-627984EAABCCQ40062728-E41775B8-6A69-4CEE-96FB-53F1BE648AD5Q40277127-D46B98A5-9095-4DDB-BD8E-2658D894CA3CQ40424356-8E2E1CFA-9016-4E22-B359-14A76FC83F0EQ40427955-7E461AA3-AC21-44BA-A6B7-69164B4A0C60Q40577692-67366B3B-8748-4B48-99AF-86402E87CEBE
P2860
A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
A randomized controlled trial ...... storage WBC-reduced platelets.
@en
type
label
A randomized controlled trial ...... storage WBC-reduced platelets.
@en
prefLabel
A randomized controlled trial ...... storage WBC-reduced platelets.
@en
P2093
P2860
P1433
P1476
A randomized controlled trial ...... storage WBC-reduced platelets.
@en
P2093
Bruce Patterson
Graham D Sher
Irwin R Walker
Jeff H Lipton
Kevin E Thorpe
Lorrie A Constantini
Mark N Levine
Morris A Blajchman
Nancy M Heddle
Ralph M Meyer
P2860
P304
P356
10.1046/J.1537-2995.2002.00094.X
P577
2002-05-01T00:00:00Z